For cryptococcosis, which regimen represents the recommended induction therapy followed by consolidation therapy?

For cryptococcosis, which regimen represents the recommended induction therapy followed by consolidation therapy?

• A. Amphotericin B + Flucytosine x 2 weeks followed by oral Fluconazole x 10 weeks
• B. Fluconazole monotherapy
• C. Itraconazole for 3-6 months
• D. Voriconazole therapy

Answer: (A)

In cryptococcal meningitis, the treatment approach is to start with rapid, potent fungal clearance (induction) and then transition to a longer period of consolidation with an oral agent. The standard induction regimen combines amphotericin B with flucytosine for about 2 weeks to aggressively reduce fungal burden in the CNS. After that, you switch to consolidation with high-dose fluconazole for roughly 8 weeks to finish eradicating the infection and prevent relapse. The regimen described—amphotericin B plus flucytosine for 2 weeks, followed by oral fluconazole for about 10 weeks—fits this induction-then-consolidation sequence and aligns with established guidelines. Fluconazole monotherapy is not sufficient for induction because it is fungistatic and slower to act against cryptococcal meningitis. Itraconazole and voriconazole are not standard first-line consolidation or induction options for CNS cryptococcosis, due to limited data or CNS penetration concerns. After consolidation, maintenance therapy with fluconazole is often continued long-term in immunocompromised patients to prevent relapse.

In cryptococcal meningitis, the treatment approach is to start with rapid, potent fungal clearance (induction) and then transition to a longer period of consolidation with an oral agent. The standard induction regimen combines amphotericin B with flucytosine for about 2 weeks to aggressively reduce fungal burden in the CNS. After that, you switch to consolidation with high-dose fluconazole for roughly 8 weeks to finish eradicating the infection and prevent relapse. The regimen described—amphotericin B plus flucytosine for 2 weeks, followed by oral fluconazole for about 10 weeks—fits this induction-then-consolidation sequence and aligns with established guidelines.

Fluconazole monotherapy is not sufficient for induction because it is fungistatic and slower to act against cryptococcal meningitis. Itraconazole and voriconazole are not standard first-line consolidation or induction options for CNS cryptococcosis, due to limited data or CNS penetration concerns. After consolidation, maintenance therapy with fluconazole is often continued long-term in immunocompromised patients to prevent relapse.